JENSCARE-B (09877) announced its interim results for the six months ended June 30, 2025, reporting revenue of RMB 13.426 million (compared to no revenue in the same period last year); gross profit of RMB 11.827 million (compared to no gross profit in the same period last year); and research and development expenses of RMB 88.885 million. According to the announcement, the revenue was primarily driven by the continued commercialization of the Group's interventional products for treating structural heart disease, resulting in increased sales volume. In the first half of 2025, the company achieved significant progress across its product pipelines in tricuspid valve, aortic valve, and mitral valve disease interventional treatment fields, forming a diversified, high-potential product portfolio. Additionally, the company continues to strengthen its international business layout, enhancing product influence and clinical application scale to solidify the foundation for long-term rapid growth.